<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of secondary hyperparathyroidism in adult patients on dialysis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of secondary hyperparathyroidism in adult patients on dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of secondary hyperparathyroidism in adult patients on dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Darryl Quarles, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic disorder characterized by biochemical abnormalities (calcium, phosphate, parathyroid hormone [PTH], and vitamin D), abnormalities in bone turnover, and extraskeletal calcification.</p><p>Secondary hyperparathyroidism refers to the biochemical abnormalities that characterize CKD-MBD.</p><p>This topic reviews the management of secondary hyperparathyroidism in patients on dialysis. The treatment of secondary hyperparathyroidism in the predialysis patient with CKD and indications for parathyroidectomy in patients with end-stage kidney disease (ESKD) are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H1336499202"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>To monitor for secondary hyperparathyroidism, we routinely measure serum levels of calcium, phosphate, and parathyroid hormone (PTH) [<a href="#rid1">1</a>]. Some clinicians use bone-specific alkaline phosphatase in addition to PTH as indication for parathyroidectomy. However, we do not believe there are sufficient high-quality data to support its use. In a large bone biopsy study, both PTH and bone-specific alkaline phosphatase were able to predict high-turnover bone disease, and the combination of the two tests added minimal additional predictive value [<a href="#rid2">2</a>].</p><p>The optimal frequency of monitoring is unknown. It is reasonable to measure phosphate and calcium levels approximately every one to three months and PTH levels every three to six months [<a href="#rid1">1</a>]. All of these levels may be assessed more frequently (ie, monthly) in response to changes in therapeutic measures that affect these levels.</p><p>Many clinicians measure vitamin D concentrations yearly.</p><p class="headingAnchor" id="H1608619523"><span class="h1">TREATMENT GOALS</span><span class="headingEndMark"> — </span>For all patients on dialysis, we suggest the following guidelines [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum levels of phosphate should be maintained between 3.5 and 5.5 mg/dL (1.13 to 1.78 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum levels of corrected total calcium should be maintained &lt;9.5 mg/dL (&lt;2.37 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid hormone (PTH) values should be maintained less than two to nine times the upper limit for the PTH assay [<a href="#rid1">1</a>].</p><p></p><p>These targets are consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [<a href="#rid3">3</a>]. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that, in patients on dialysis, elevated phosphate levels should be lowered toward the normal range; however, a specific target level is not given. We believe that clearer guidance is needed.</p><p>The target value of 5.5 mg/dL was suggested by a meta-analysis of 12 studies that included 92,345 patients with chronic kidney disease (CKD), over 97 percent of whom were on dialysis [<a href="#rid4">4</a>]. Among 10 studies that were perceived to be adequately adjusted (in which seven studies were of patients on dialysis), serum phosphate &gt;5.5 mg/dL (1.78 mmol/L) was associated with increased mortality. Based upon 13 studies that reported a continuous relative risk for each mg/dL increase in phosphate, the mortality risk increased by 18 percent (95% CI 1.12-1.25).</p><p>There are no studies that have conclusively shown that outcomes are improved by treatment-related reduction of phosphate [<a href="#rid5">5</a>]. Some observational studies have suggested that patients on dialysis prescribed phosphate binders have improved survival [<a href="#rid6">6-8</a>].</p><p>Once hyperphosphatemia is treated, we treat PTH values that are persistently more than two to nine times the upper limit for the PTH assay [<a href="#rid1">1</a>]. Because of variability in assays, an absolute PTH threshold for treatment should not be specified, and decisions regarding treatment should be based upon trends rather than single laboratory values [<a href="#rid1">1</a>].</p><p>Numerous studies have suggested that the high-turnover bone disorders, osteitis fibrosa and mixed uremic osteodystrophy, are associated with serum levels of intact PTH &gt;400 pg/mL (ie, approximately six times the upper limit of normal of 65 pg/mL) [<a href="#rid9">9,10</a>].</p><p>Suppression of PTH to less than two times the upper limit for the specific PTH assay is not desirable, since it is associated with a higher prevalence of adynamic bone disease [<a href="#rid5">5,11</a>]. (See  <a class="medical medical_review" href="/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H605165927"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3065667719"><span class="h2">Treat hyperphosphatemia</span><span class="headingEndMark"> — </span>Persistently high phosphate (ie, &gt;5.5 mg/dL) should be treated before treating high parathyroid hormone (PTH). Specific therapies for high PTH may increase the serum phosphate.</p><p>Decisions regarding treatment of hyperphosphatemia should be based upon trends rather than single laboratory values [<a href="#rid1">1</a>]. Specific treatment approaches are discussed elsewhere [<a href="#rid1">1,3,5-8,12</a>]. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Treatment approach'</a>.)</p><p class="headingAnchor" id="H1029767940"><span class="h2">Maintain normocalcemia</span><span class="headingEndMark"> — </span>It is important to maintain serum calcium &lt;9.5 mg/dL (&lt;2.37 mmol/L). We do not specifically treat asymptomatic and mild hypocalcemia (ie, &gt;7.5 mg/dL in the setting of normal albumin) with either calcium or vitamin D derivatives (such as <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or synthetic vitamin D analogs). There is a significant risk of hypercalcemia with these agents.</p><p class="headingAnchor" id="H646939004"><span class="h2">Treat vitamin D deficiency</span><span class="headingEndMark"> — </span>We correct vitamin D deficiency [<a href="#rid1">1</a>]. Limited evidence from a nested case-control study suggests that low vitamin D levels are associated with increased early mortality among patients on hemodialysis [<a href="#rid13">13</a>].</p><p>We use a similar treatment strategy as is recommended for the general population. (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a>.)</p><p>Among patients on hemodialysis, both <a class="drug drug_general" data-topicid="10150" href="/d/drug information/10150.html" rel="external">ergocalciferol</a> and <a class="drug drug_general" data-topicid="10117" href="/d/drug information/10117.html" rel="external">cholecalciferol</a> are effective in repleting vitamin D levels [<a href="#rid14">14-17</a>].</p><p>Other than accomplishing nutritional repletion, there is no conclusive evidence to support a benefit of vitamin D replacement in patients on dialysis. Nevertheless, there is no significant toxicity associated with its use in this setting, although long-term studies have not been performed. In particular, studies have shown no difference in risk of hypercalcemia, hyperphosphatemia, or vascular calcification among vitamin-D-treated patients [<a href="#rid14">14-17</a>].</p><p class="headingAnchor" id="H623121505"><span class="h2">Treat high parathyroid hormone</span></p><p class="headingAnchor" id="H3139979101"><span class="h3">Treatment options</span><span class="headingEndMark"> — </span>Treatment options for increased PTH include calcimimetics, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>, or synthetic vitamin D analogs [<a href="#rid5">5</a>]. A combination of calcimimetics with calcitriol or synthetic vitamin D analogs may also be used.</p><p>The Kidney Disease: Improving Global Outcomes (KDIGO) work group was divided as to whether calcimimetics, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>/synthetic vitamin D analogs, or a combination of the two be regarded as first-line therapy [<a href="#rid1">1</a>].</p><p>All approaches reduce PTH. No studies have convincingly demonstrated a benefit on patient-centered outcomes.</p><p class="headingAnchor" id="H3838792441"><span class="h4">Calcitriol and synthetic vitamin D analogs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">Calcitriol</a> (oral or intravenous [IV]) and synthetic vitamin D analogs all reduce PTH [<a href="#rid13">13,18-20</a>], although these agents are not sufficiently effective as monotherapy if the PTH is very high [<a href="#rid21">21,22</a>].</p><p>No randomized trials have shown a convincing benefit of <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or synthetic vitamin D analogs on survival, bone pain, in preventing parathyroidectomy, or other important clinical outcomes [<a href="#rid23">23,24</a>].</p><p><a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">Calcitriol</a> or synthetic vitamin D analogs should be avoided, administered at a low dose, or discontinued if the serum phosphate exceeds 5.5 mg/dL or if the serum calcium exceeds 10.2 mg/dL [<a href="#rid3">3</a>]. However, they may be continued if there is a clearly reversible cause identified for hypercalcemia (eg, nonadherence to <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a>) or hyperphosphatemia (eg, nonadherence to phosphate binders).</p><p>After resolution of hypercalcemia or hyperphosphatemia, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or the synthetic vitamin D analog can be resumed at one-half the previous dose, or <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> therapy can be initiated or its dose increased. Calcitriol and synthetic vitamin D analogs increase serum calcium and phosphorus, which can cause metastatic calcification and vascular calcification.</p><p>Six active (ie, 1-hydroxylated) vitamin D derivatives are available. These include <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> [<a href="#rid25">25,26</a>] and five synthetic vitamin D analogs: <a class="drug drug_general" data-topicid="10197" href="/d/drug information/10197.html" rel="external">paricalcitol</a> [<a href="#rid19">19,27</a>], <a class="drug drug_general" data-topicid="8651" href="/d/drug information/8651.html" rel="external">doxercalciferol</a> [<a href="#rid28">28-30</a>], <a class="drug drug_general" data-topicid="16467" href="/d/drug information/16467.html" rel="external">alfacalcidol</a> (not available in the United States) [<a href="#rid31">31-33</a>], falecalcitriol (not available in the United States), and 22-oxacalcitriol (not available in the United States) [<a href="#rid26">26,34-36</a>]. All of the available vitamin D derivatives are considered acceptable, and there are no convincing studies that support one particular agent over another [<a href="#rid37">37</a>]. As an example, in one observational study of patients on hemodialysis, three vitamin D derivatives (calcitriol, paricalcitol, and doxercalciferol) were associated with similar rates of calcium, phosphate, and PTH control, as well as similar rates of hospitalization and survival [<a href="#rid38">38</a>]. </p><p>In general, the starting dose of <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>, whether oral or IV, or of the vitamin D analog should be low (eg, 0.25 mcg thrice weekly). Dose adjustments may be made at four- to eight-week intervals. Patients who are responsive to therapy typically show significant reductions in PTH levels within the first three to six months of therapy [<a href="#rid11">11,21,29,39-46</a>].</p><p class="headingAnchor" id="H217791874"><span class="h4">Calcimimetics</span><span class="headingEndMark"> — </span>The calcium-sensing receptor (CaSR) of the parathyroid gland regulates secretion of PTH. Calcimimetics increase the sensitivity of the CaSR to calcium [<a href="#rid47">47</a>], thereby reducing the plasma PTH concentration and, in turn, decreasing the serum calcium and phosphate levels [<a href="#rid48">48-63</a>]. However, despite the improved control of hyperparathyroidism, their use has not been shown to improve cardiovascular or all-cause mortality among patients on dialysis [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/2050.html" rel="external">"Parathyroid hormone secretion and action", section on 'Calcimimetic drugs'</a>.)</p><p>Widely available calcimimetics include <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> (oral) and <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> (intravenous). When a calcimimetic is indicated, we prefer cinacalcet over etelcalcetide because it is relatively inexpensive and has a similar adverse event profile. We use etelcalcetide among patients who fail to respond sufficiently to cinacalcet. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cinacalcet</strong><strong> ─</strong> The addition of <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> to current treatment regimens (usually <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or an active vitamin D analog plus phosphate binder) increases the chances of decreasing PTH to target values without causing hypercalcemia or hyperphosphatemia [<a href="#rid55">55,59,61,62,64</a>]. Cinacalcet also decreases the chances of requiring a parathyroidectomy [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">However, among patients with advanced secondary hyperparathyroidism (baseline PTH levels above 800 pg/mL), monotherapy with <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> may be inadequate to control PTH [<a href="#rid66">66</a>]. Such patients might be better treated with combination therapy of an active vitamin D analog and cinacalcet.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">Cinacalcet</a> does not appear to provide a benefit on mortality and cardiovascular outcomes, at least among patients &lt;65 years of age [<a href="#rid65">65,67</a>]. In the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) randomized trial, patients were assigned to receive cinacalcet or placebo in addition to conventional therapy including phosphate binders and/or active vitamin D or synthetic analogs [<a href="#rid67">67</a>]. At a median follow-up of less than two years, a difference between groups in the composite outcome of time until death or the first nonfatal cardiovascular event was not shown.</p><p></p><p class="bulletIndent1">The interpretation of this trial is limited by both a high dropout rate in the <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> group (62 percent) and a high rate of crossover in the placebo group: Nearly 20 percent of patients in the placebo group ended up taking commercially available cinacalcet. The high rate of crossover may have diminished between-group differences.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">Cinacalcet</a> may provide a benefit to older individuals, who are at higher cardiovascular risk compared with younger patients. In EVOLVE, the effect of cinacalcet was examined among patients on hemodialysis who were ≥65 years (n = 1005) and &lt;65 years (n = 2878) [<a href="#rid68">68</a>]. Among older patients, cinacalcet reduced the risk of major cardiovascular events (adjusted hazard ratio [AHR] 0.70, 95% CI 0.60-0.81) and death (AHR 0.68, 95% CI 0.51-0.81). Among younger patients, the cinacalcet-associated AHRs for cardiovascular events and mortality were 0.97 (95% CI 0.86-1.09) and 0.99 (95% CI 0.86-1.13), respectively. The effect of cinacalcet on severe hyperparathyroidism was the same between older and younger individuals.</p><p></p><p class="bulletIndent1">There was also a trend toward a decreased fracture risk among individuals ≥65 years who were treated with <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> (AHR 0.69, 95% CI 0.49-0.95) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">Side effects of <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> noted in the EVOLVE trial included hypocalcemia and gastrointestinal symptoms [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etelcalcetide</strong><strong> ─</strong> Intravenous <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> was compared with placebo and with oral <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> in three randomized trials [<a href="#rid70">70,71</a>]. All trials were of short duration and did not examine patient-important outcomes [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">In two parallel randomized trials, <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> was compared with placebo among a total of 1023 patients on hemodialysis with hyperparathyroidism [<a href="#rid70">70</a>]. Etelcalcetide was more effective than placebo in reducing PTH (with 74 to 75 percent of patients achieving &gt;30 percent reduction in PTH versus 8.3 to 9.6 percent in placebo) by 27 weeks. However, etelcalcetide-treated patients had more side effects compared with placebo (hypocalcemia, muscle spasms, nausea and vomiting).</p><p></p><p class="bulletIndent1">A randomized trial compared intravenous <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> versus oral placebo (n = 340) and oral <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> versus intravenous placebo (n = 343) among patients on hemodialysis with hyperparathyroidism [<a href="#rid71">71</a>]. Etelcalcetide was superior to cinacalcet in reducing PTH by greater than 30 percent (68 in etelcalcetide groups versus 58 percent in cinacalcet group).</p><p></p><p class="bulletIndent1">Nausea and vomiting were comparable between groups. However, hypocalcemia was more common in the <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> group and required interventions to increase serum calcium concentrations (such as raising the dialysate calcium concentrations and prescribing calcium-containing phosphate binders, oral calcium supplements, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>, and active vitamin D analogs). Etelcalcetide administration led to prolongation of corrected QT intervals in many patients. Because it is administered intravenously, compliance can be assured.</p><p></p><p class="headingAnchor" id="H3055333583"><span class="h3">Treatment approach</span><span class="headingEndMark"> — </span>Both drug classes lower PTH levels but have disparate effects on calcium and phosphate levels; thus, we choose different treatment approaches based on serum phosphate and calcium levels. Our approach is largely consistent with the 2017 KDIGO guidelines [<a href="#rid1">1</a>].</p><p>We treat patients with phosphate &lt;5.5 mg/dL (&lt;1.78 mmol/L) and calcium &lt;9.5 mg/dL (&lt;2.37 mmol/L) with <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> monotherapy. However, other vitamin D analogs are also effective in reducing PTH. (See <a class="local">'Calcitriol and synthetic vitamin D analogs'</a> above.)</p><p>Some clinicians treat such patients with a calcimimetic rather than <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or a synthetic vitamin D analog, although studies have not shown a convincing benefit of <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> on important clinical outcomes (see <a class="local">'Calcimimetics'</a> above). Cinacalcet should not be used if the serum calcium level is &lt;8.4 mg/dL (&lt;2.1 mmol/L), since it lowers calcium concentration. Such patients are treated with calcitriol.</p><p>Our dosing strategy is empiric, with the goal of administering increasing doses of <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or synthetic vitamin D analogs to achieve target plasma PTH level while maintaining serum phosphate ≤5.5 mg/dL [<a href="#rid3">3</a>]. Measures to maintain goal serum phosphate values are used concurrently. (See <a class="local">'Treat hyperphosphatemia'</a> above and  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Patients on dialysis'</a>.)</p><p>Among patients with inadequate reduction of PTH on <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>, we add <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a>, provided the calcium is &gt;8.4 mg/dL. Up to one-half of patients with severe hyperparathyroidism show little or no decline in plasma PTH levels with calcitriol therapy [<a href="#rid21">21,22</a>]. The addition of cinacalcet increases the chances of achieving target PTH values and allows the use of lower doses of the vitamin D analog, which are less likely to cause hypercalcemia or hyperphosphatemia [<a href="#rid55">55,59,61,62,64,73,74</a>].</p><p><a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">Cinacalcet</a> is initiated at a dose of 30 mg/day orally, with stepwise increments to 60, 90, and 180 mg/day. The dose can be increased every four weeks until goals are achieved. We use <a class="drug drug_general" data-topicid="111821" href="/d/drug information/111821.html" rel="external">etelcalcetide</a> among patients who fail to respond sufficiently to cinacalcet. (See <a class="local">'Calcimimetics'</a> above.)</p><p>Among patients with serum phosphate ≥5.5 mg/dL (≥1.78 mmol/L) or serum calcium level ≥9.5 mg/dL (≥2.37 mmol/L) and persistently elevated PTH, despite maximal therapies to reduce phosphate, we initiate therapy with a calcimimetic rather than <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or a synthetic vitamin D analog. Calcitriol and synthetic vitamin D analogs should not be used in such patients at least initially, since they both raise serum calcium and phosphate levels.</p><p>Calcimimetics should not be started if serum calcium is &lt;8.4 mg/dL (&lt;2.1 mmol/L), since these agents cause low calcium [<a href="#rid75">75</a>].</p><p>During treatments, serum levels of corrected total calcium should be maintained between 8.4 and 9.5 mg/dL (2.10 to 2.37 mmol/L).</p><p>Among patients who do not sufficiently reduce PTH with <a class="drug drug_general" data-topicid="8850" href="/d/drug information/8850.html" rel="external">cinacalcet</a> alone, we add <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> or a synthetic vitamin D analog, providing the phosphate &lt;5.5 mg/dL (&lt;1.78 mmol/L) and calcium &lt;9.5 mg/dL (&lt;2.37 mmol/L).</p><p class="headingAnchor" id="H1667210101"><span class="h1">REFRACTORY HYPERPARATHYROIDISM</span><span class="headingEndMark"> — </span>We define refractory hyperparathyroidism as persistent and progressive elevations of serum parathyroid hormone (PTH) that cannot be lowered to levels &lt;600 pg/mL despite treatment with vitamin D derivatives and calcimimetics and without causing significant hyperphosphatemia or hypercalcemia. Patients with severe disease may require parathyroidectomy [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p class="headingAnchor" id="H420237272"><span class="h1">MEDICAL TREATMENT FOLLOWING PARATHYROIDECTOMY</span><span class="headingEndMark"> — </span>Patients who have had a parathyroidectomy for tertiary hyperparathyroidism should be managed the same as others with end-stage kidney disease (ESKD) and secondary hyperparathyroidism with respect to goals and medical therapy.</p><p class="headingAnchor" id="H3451874750"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Among patients on dialysis, we measure serum levels of phosphate and calcium levels approximately every one to three months and parathyroid hormone (PTH) levels every three to six months. We measure vitamin D concentrations yearly. All of these levels may be assessed more frequently in response to changes in therapeutic measures that affect these levels. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treat hyperphosphatemia</strong> – We treat hyperphosphatemia prior to treating hyperparathyroidism. Observational studies have suggested increased mortality at serum phosphate values above 5.5 mg/dL. (See <a class="local">'Treat hyperphosphatemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – We suggest treating PTH values that are more than two to nine times the upper limit for the PTH assay (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Studies have suggested that the high-turnover bone disorders are associated with serum levels of PTH &gt;400 pg/mL (ie, approximately six times upper limit of normal of 65 pg/mL). We maintain serum calcium &lt;9.5 mg/dL (&lt;2.37 mmol/L). (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1">We suggest not suppressing PTH to less than or equal to two times the upper limit for the PTH assay (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Oversuppression of PTH is associated with adynamic bone disease. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong> – Treatment options for increased PTH include calcimimetics, <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a>, or synthetic vitamin D analogs. A combination of calcimimetics with calcitriol or synthetic vitamin D analogs may also be used. All approaches reduce PTH, but no studies have shown a benefit on patient-centered outcomes. Our approach depends on the serum phosphate and calcium concentrations. (See <a class="local">'Treatment approach'</a> above.)</p><p></p><p class="headingAnchor" id="H194478992"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert E Cronin, MD, and Michael Berkoben, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.</a></li><li><a class="nounderline abstract_t">Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.</a></li><li><a class="nounderline abstract_t">Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305:1119.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li><li><a class="nounderline abstract_t">Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84:998.</a></li><li><a class="nounderline abstract_t">Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388.</a></li><li><a class="nounderline abstract_t">Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60:90.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771.</a></li><li><a class="nounderline abstract_t">Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52:519.</a></li><li><a class="nounderline abstract_t">Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42:1191.</a></li><li><a class="nounderline abstract_t">Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant 2015; 30:1542.</a></li><li><a class="nounderline abstract_t">Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004.</a></li><li><a class="nounderline abstract_t">Massart A, Debelle FD, Racapé J, et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis 2014; 64:696.</a></li><li><a class="nounderline abstract_t">Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105:c132.</a></li><li><a class="nounderline abstract_t">Delanaye P, Weekers L, Warling X, et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 2013; 28:1779.</a></li><li><a class="nounderline abstract_t">Bhan I, Dobens D, Tamez H, et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 2015; 10:611.</a></li><li><a class="nounderline abstract_t">Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115.</a></li><li><a class="nounderline abstract_t">Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446.</a></li><li><a class="nounderline abstract_t">Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19:179.</a></li><li><a class="nounderline abstract_t">Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45:1710.</a></li><li><a class="nounderline abstract_t">Malberti F, Corradi B, Cosci P, et al. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996; 28:704.</a></li><li><a class="nounderline abstract_t">Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147:840.</a></li><li><a class="nounderline abstract_t">Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2007; 147:880.</a></li><li><a class="nounderline abstract_t">Slatopolsky E, Berkoben M, Kelber J, et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992; 38:S43.</a></li><li><a class="nounderline abstract_t">Finch JL, Brown AJ, Kubodera N, et al. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43:561.</a></li><li><a class="nounderline abstract_t">Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63:1483.</a></li><li><a class="nounderline abstract_t">Frazão JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36:550.</a></li><li><a class="nounderline abstract_t">Maung HM, Elangovan L, Frazão JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37:532.</a></li><li><a class="nounderline abstract_t">Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70:1858.</a></li><li><a class="nounderline abstract_t">Ljunghall S, Althoff P, Fellström B, et al. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis. Nephron 1990; 55:380.</a></li><li><a class="nounderline abstract_t">Matuszkiewicz-Rowińska J, Niemczyk S, Pacocha E, et al. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure]. Pol Arch Med Wewn 1996; 96:15.</a></li><li><a class="nounderline abstract_t">Ritzerfeld M, Klasser M, Mann H. Alfacalcidol in the therapy of renal bone disease. Int J Clin Pharmacol Ther 2001; 39:546.</a></li><li><a class="nounderline abstract_t">Kurokawa K, Akizawa T, Suzuki M, et al. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 1996; 11 Suppl 3:121.</a></li><li><a class="nounderline abstract_t">Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35:458.</a></li><li><a class="nounderline abstract_t">Tamura S, Ueki K, Mashimo K, et al. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 2005; 9:238.</a></li><li><a class="nounderline abstract_t">Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial 2019; 23:73.</a></li><li><a class="nounderline abstract_t">Thadhani RI, Rosen S, Ofsthun NJ, et al. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Clin J Am Soc Nephrol 2020; 15:384.</a></li><li><a class="nounderline abstract_t">Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000; 57:282.</a></li><li><a class="nounderline abstract_t">Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74:2136.</a></li><li><a class="nounderline abstract_t">Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989; 83:1349.</a></li><li><a class="nounderline abstract_t">Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321:274.</a></li><li><a class="nounderline abstract_t">Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7:488.</a></li><li><a class="nounderline abstract_t">Mazess RB, Elangovan L. A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol 2003; 59:319.</a></li><li><a class="nounderline abstract_t">Quarles LD, Davidai GA, Schwab SJ, et al. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34:840.</a></li><li><a class="nounderline abstract_t">Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83:66.</a></li><li><a class="nounderline abstract_t">Nemeth EF, Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 1998; 13:1923.</a></li><li><a class="nounderline abstract_t">Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998; 53:223.</a></li><li><a class="nounderline abstract_t">Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58:436.</a></li><li><a class="nounderline abstract_t">Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13:1017.</a></li><li><a class="nounderline abstract_t">Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63:248.</a></li><li><a class="nounderline abstract_t">Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14:575.</a></li><li><a class="nounderline abstract_t">Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516.</a></li><li><a class="nounderline abstract_t">Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004; 44:1070.</a></li><li><a class="nounderline abstract_t">Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67:760.</a></li><li><a class="nounderline abstract_t">Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16:800.</a></li><li><a class="nounderline abstract_t">Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. Kidney Int Suppl 2004; :S46.</a></li><li><a class="nounderline abstract_t">Sterrett JR, Strom J, Stummvoll HK, et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68:10.</a></li><li><a class="nounderline abstract_t">Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3:36.</a></li><li><a class="nounderline abstract_t">Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009; 4:1465.</a></li><li><a class="nounderline abstract_t">Arenas MD, Alvarez-Ude F, Gil MT, et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22:1639.</a></li><li><a class="nounderline abstract_t">Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3:1718.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Johnson DW, et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis 2020; 76:321.</a></li><li><a class="nounderline abstract_t">Amgen Sensipar clears FDA: Phosphate binders are a competitive target. FDC Rep Drugs Cosmet 2004; 66:23.</a></li><li><a class="nounderline abstract_t">Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10:e1001436.</a></li><li><a class="nounderline abstract_t">Wetmore JB, Gurevich K, Sprague S, et al. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 2015; 10:1031.</a></li><li><a class="nounderline abstract_t">EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482.</a></li><li><a class="nounderline abstract_t">Parfrey PS, Drüeke TB, Block GA, et al. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 2015; 10:791.</a></li><li><a class="nounderline abstract_t">Moe SM, Abdalla S, Chertow GM, et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol 2015; 26:1466.</a></li><li><a class="nounderline abstract_t">Block GA, Bushinsky DA, Cunningham J, et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017; 317:146.</a></li><li><a class="nounderline abstract_t">Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317:156.</a></li><li><a class="nounderline abstract_t">Middleton JP, Wolf M. Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic. JAMA 2017; 317:139.</a></li><li><a class="nounderline abstract_t">Chertow GM, Blumenthal S, Turner S, et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1:305.</a></li><li><a class="nounderline abstract_t">Wang AY, Lo WK, Cheung SC, et al. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial. Nephrol Dial Transplant 2023; 38:1823.</a></li><li><a class="nounderline abstract_t">Amgen Sensipar label prepares for off-label use in pre-dialysis population. Pharmaceutical Approvals Monthly 2004; 9:28.</a></li></ol></div><div id="topicVersionRevision">Topic 1918 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28646995" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321176" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406649" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23823605" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Use of phosphate-binding agents is associated with a lower risk of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092121" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phosphorus binders and survival on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385781" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820797" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514987" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453603" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25920921" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687259" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vitamin D levels and early mortality among incident hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24856872" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17228173" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378417" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770176" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nutritional vitamin D supplementation in dialysis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728786" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Activated injectable vitamin D and hemodialysis survival: a historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890843" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671054" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933819" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158208" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18087055" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Meta-analysis: vitamin D compounds in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18087060" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vitamin D in patients with chronic kidney disease: nothing new under the sun.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405381" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8455354" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631365" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10977787" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228177" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021609" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mortality risk among hemodialysis patients receiving different vitamin D analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2392190" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8966141" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11770836" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alfacalcidol in the therapy of renal bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8840326" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10692271" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189633" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30328270" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32111702" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620210" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6549016" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2703535" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2631697" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704116" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779092" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3210546" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910921" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9719139" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tricking the parathyroid gland with novel calcimimetic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453023" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886592" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912261" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472790" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595492" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071126" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558528" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673327" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689407" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15296507" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17703830" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178780" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696213" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277339" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945995" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32475604" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Amgen Sensipar clears FDA: Phosphate binders are a competitive target</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23637579" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904755" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121374" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710802" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25505257" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097355" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097356" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097342" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699221" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36869794" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Amgen Sensipar label prepares for off-label use in pre-dialysis population</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
